New Guidance Effective Immediately for Testing of Glycerin, Propylene, Other High Risk Drug Components
The guidance is to provide information on compliance with applicable regulatory requirements and recommendations.
The new guidance from FDA is set to alert pharmaceutical manufacturers, compounders, repackers, and suppliers to the potential public health hazard of glycerin and other high-risk drug components contaminated with diethylene glycol (DEG) or ethylene glycol (EG). This comes from the frequent reports to FDA about fatal poisonings of consumers who ingested drug products in a liquid dosage form, like cough or allergy drug products, that were manufactured using DEG- or EG-contaminated components.
Further, the guidance is to provide information on compliance with applicable regulatory requirements and recommendations to help pharmaceutical manufacturers, repackers, other suppliers of high-risk drug components, and compounders prevent the use of glycerin and other high-risk drug components that are contaminated with DEG or EG.
Source: FDA
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
